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Development and Evaluation of Therapeutics in the Setting of Radiation Injury
Abstract
The possibility of an incident involving radiation exposure is at the forefront of public attention in the
current global environment. With a greater number of entities possessing nuclear weapons and increased
demand for nuclear power, the concern for uncontained exposure to radiation is increasing. In light of
these developments, the need for treatments that may be easily stored and administered to large
numbers of people who have been exposed to high doses of total body irradiation (TBI) is more urgent
than ever before.
Our goal was to identify and develop novel, drug-like small molecules that would exhibit radiomitigating
activity for use in Acute Radiation Syndrome (ARS). Hot water extracts of Cat’s Claw containing quinic
acid have been shown to possess activity in increasing circulating white blood cells as well as promoting
DNA repair. Our group previously synthesized and evaluated a series of quinic acid derivatives. Quinic acid
derivative KZ-41 was identified and described as highly water soluble and orally available. We have,
therefore, identified a novel quinic acid derivative, KZ-41, as our initial lead molecule for evaluation,
characterization, and development in the setting of ARS.
Initial efficacy was tested in vivo by evaluating the impact KZ-41 had on the primary endpoint of mortality
in lethally irradiated C57BL/6 mice 30 days after exposure. To investigate the potential mechanisms
related to the enhanced survival following TBI, we investigated the effect of KZ-41 on parameters
important to initial wound healing. We developed an imaging model to specifically investigate the effect
of KZ-41 on clotting following TBI and vascular injury. This model also allowed us to gain insight into
“combined injury” which is also of critical importance when discussing the “real-life” implications of ARS. .
To further evaluate mechanisms of effect, we developed an in vitro model using human monocytes
(U937) cells. Using the in vitro model developed, we characterized the effect KZ-41 had on intrinsic and
extrinsic apoptotic cell death, focusing on the impact in the “bystander effect” model. We also utilized the
in vitro model to identify potential more potent analogues and next-generation compounds. Initial preclinical pharmacokinetic characterization of a next-generation compound was also conducted.
We have shown KZ-41 to be effective in improving survival of lethally irradiated mice, enhancing the
critical wound healing events of initial thrombus formation and in restoring vascular flow in combined
injury. In an in vitro bystander effect model, KZ-41 can mitigate apoptosis when administered after the
radiation event. Initial, identification, and pharmacokinetic characterization of a potent next-generation
compound for use in ARS is also described herein.
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ABSTRACT
The possibility of an incident involving radiation exposure is at the forefront of
public attention in the current global environment. With a greater number of entities
possessing nuclear weapons and increased demand for nuclear power, the concern for
uncontained exposure to radiation is increasing. In light of these developments, the need
for treatments that may be easily stored and administered to large numbers of people who
have been exposed to high doses of total body irradiation (TBI) is more urgent than ever
before.
Our goal was to identify and develop novel, drug-like small molecules that would
exhibit radiomitigating activity for use in Acute Radiation Syndrome (ARS). Hot water
extracts of Cat’s Claw containing quinic acid have been shown to possess activity in
increasing circulating white blood cells as well as promoting DNA repair. Our group
previously synthesized and evaluated a series of quinic acid derivatives. Quinic acid
derivative KZ-41 was identified and described as highly water soluble and orally
available. We have, therefore, identified a novel quinic acid derivative, KZ-41, as our
initial lead molecule for evaluation, characterization, and development in the setting of
ARS.
Initial efficacy was tested in vivo by evaluating the impact KZ-41 had on the
primary endpoint of mortality in lethally irradiated C57BL/6 mice 30 days after exposure.
To investigate the potential mechanisms related to the enhanced survival following TBI,
we investigated the effect of KZ-41 on parameters important to initial wound healing.
We developed an imaging model to specifically investigate the effect of KZ-41 on
clotting following TBI and vascular injury. This model also allowed us to gain insight
into “combined injury” which is also of critical importance when discussing the “reallife” implications of ARS. .
To further evaluate mechanisms of effect, we developed an in vitro model using
human monocytes (U937) cells. Using the in vitro model developed, we characterized
the effect KZ-41 had on intrinsic and extrinsic apoptotic cell death, focusing on the
impact in the “bystander effect” model. We also utilized the in vitro model to identify
potential more potent analogues and next-generation compounds. Initial pre-clinical
pharmacokinetic characterization of a next-generation compound was also conducted.
We have shown KZ-41 to be effective in improving survival of lethally irradiated
mice, enhancing the critical wound healing events of initial thrombus formation, and in
restoring vascular flow in combined injury. In an in vitro bystander effect model, KZ-41
can mitigate apoptosis when administered after the radiation event. Initial identification
and pharmacokinetic characterization of a potent next-generation compound for use in
ARS is also described herein.
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CHAPTER 1. INTRODUCTION
ACUTE RADIATION SYNDROME
There is growing concern that the potential for nuclear attack is increasing. Small
scale attacks could involve hundreds to thousands of people exposed to total body
irradiation (TBI) [1]. Acute radiation syndrome (ARS) results from radiation exposures
greater than 1 Gy, to a significant portion of the body delivered at a relatively high dose
rate. Such radiation exposure can be from a nuclear accident (e.g., Chernobyl), from a
military event (e.g., Hiroshima and Nagasaki), or through a terrorist incident. ARS
encompasses overlapping syndromes including hematopoietic (Hem-ARS),
gastrointestinal, and neurological syndromes (Figure 1-1). Victims whose TBI dose
ranges from 2-6 Gy, known as the hematopoietic syndrome, will be most likely to be
saved with treatment, and it is estimated that nearly all persons exposed to doses greater
than 6 Gy will die within 30 days of exposure if not treated [2].
Hematopoietic Syndrome
Hematopoietic stem cells are extremely vulnerable to γ-irradiation whose damage
is the cause of Hem-ARS which occurs at the lowest radiation doses and is observed with
increasing severity proportional to radiation dose (Figure 1-2). Symptoms of moderate
Hem-ARS is due to exposure to levels of ionizing radiation greater than 1-2 Gray, and
manifests as bone marrow damage (Figure 1-3) [3]. Severe Hem-ARS is seen at ionizing
radiation doses from 4 Gy [2, 4]. It is estimated that without supportive care (antibiotics
and transfusions), a radiation dose of approximately 3.5-4.5 Gy will result in death of
50% of persons exposed within 60 days (LD 50/60 ) [3, 5, 6]. While ARS can affect many
organ systems (e.g., dermal, cardiovascular) primary causes of morbidity and mortality in
Hem-ARS are related to pancytopenia. Death resulting from sepsis results from a
decrease in innate immunity, both the numbers of circulating leukocytes and possibly the
function [7, 8]. Hemorrhage associated mortality can be correlated with a significant
decrease in circulating platelet levels and magakaryocyte precursors. In the event of a
nuclear accident or attack, there will be other injuries in addition to the radiation
exposure. It has been estimated that as many as 60-70% of ARS patients will have other
injuries, and these patients will have a significantly lower LD 50/60 [5]. Additional injuries
increase the probability of introduction of infection that a compromised hematopoietic
system cannot combat. Hematopoietic recovery must be attained or the patient will have
no chance to recover from other injuries [9]. Therefore, hematopoietic support is
essential at all radiation doses relevant to induce ARS.
Gastrointestinal Syndrome
Total body doses above approximately 8 Gy will involve serious injury to the
gastrointestinal (GI) system, contributing to mortality [10]. Radiation doses from around
1

Figure 1-1 Radiation Doses Associated with Acute Radiation Syndrome.

Figure 1-2 Differientation of Hematopoietic Progenitor Cells.
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Normal

Reduced After IR

Figure 1-3 Effect of Radiation on Bone Marrow Cellularity.
Normal bone marrow cellularity is dense as demonstrated by the panel on the left. The
panel on the right indicates reduced cellularity in the bone marrow after high dose
irradiation.
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8-30 Gy elicit effects known as the GI syndrome. Damage to intestinal mucosal stem
cells is the hallmark of the GI syndrome. The result of the damage to the intestine is
decreased barrier function and abnormal absorption. Clinical symptoms of GI-ARS
include nausea, vomiting, and diarrhea in addition to those of the hematopoietic
syndrome, impaired immune function being of particular importance [2]. Since ARS
sub-syndromes overlap, patients faced with the GI syndrome are still highly susceptible
to hemorrhage and infections due to a depressed immune system. Decreased intestinal
epithelial barrier function results in an increased risk of bacterial translocation into the
blood, and coupled with a diminished ability to combat infection, results in an increased
incidence of sepsis and death and a marked shift in the mortality curve.
Neurological Syndrome
Total body doses above approximately 30 Gy will elicit the neurological (CNS)
syndrome due primarily to hypotension and cerebral edema. At CNS syndrome doses,
cardiovascular damage also occurs and death occurs within hours to days [2]. Symptoms
include loss of consciousness in addition to all of those experienced in the hematopoietic
and gastrointestinal syndrome with a more severe and rapid onset. The CNS syndrome is
the least studied due to the fact that very few accident victims worldwide have
encountered this extremely high dose. It must be noted, however, that even at nonlethal
ARS radiation doses neurological effects may be seen after several days manifested by
lower response rates [11, 12]. Under the current understanding of the biophysical
pathways and effects elicited by these very high doses of TBI, it is unlikely that a
survival advantage could be obtained.
Clinical Progression of ARS
Time to Onset. Symptoms of ARS may be seen as early as 1-2 hours after
exposure. Symptoms include vomiting, diarrhea, headache, altered consciousness, fever,
and hematological changes. As radiation dose increases, symptoms become more severe
and appear earlier [2, 8]. There are three phases describing the progression of ARS: (1)
Prodromal, (2) Latent phase, and (3) Critical Phase. The prodromal phase occurs very
soon after exposure and may include mild to moderate physical symptoms, but is rarely
lethal. Following the prodromal phase, there is a latent period lasting a variable amount
of time, depending on the absorbed dose. The length of the latent period ranges from 035 days and is inversely related to the radiation dose. The latent phase is often free from
manifested symptoms. The critical phase is defined as the peak of bone marrow
depression resulting in leucopenia and thrombocytopenia and occurs sooner as the dose
increases. Death due to infection and hemorrhage tend to correlate with this nadir [2, 13].
Hematological Kinetics. The myelosupression resulting from TBI is dosedependent [13]. Irreversible injury shows initial granulocytosis and progressive decline
of cell counts to nadir around day 6. The initial granulocytosis is due to rapid
mobilization of granulocytes from reserve pools, and the approximate 4 day maturation
4

time of granulocytes in the bone marrow. Assuming irreversible injury (all pre-cursor
cells in the bone marrow have been destroyed), once these cells have appeared in the
blood, the decline occurs rapidly. A normal lymphocyte count in an adult is 1.4-3.9 x
104/L [14]. Lymphocytes show progressive decline and nadir within 48 hours. This
rapid decline is not a result of radiation sensitivity of the lymphocyte, but rather an
impaired ability to re-circulate. Therefore, lymphocyte decline is not necessarily
indicative of degree of bone marrow damage, however, a 50% decline at 24 hours after
exposure may indicate a lethal radiation dose has been absorbed (Figure 1-4) [14].
Platelets show progressive decline over the first 10 days with nadir at day 10. This linear
decline in platelets over 10 days is reflective of the survival time of circulating platelets
and indicative of all megakaryocyte precursors in the bone marrow having been
destroyed. Reversible injury shows moderate initial granulocytosis and decline between
days 4-10, an abortive recovery and nadir at days 20-30. Lymphocytes show nadir within
2 days, and slow recovery (over ~ 25 days). Platelets show an initial 10 day shoulder,
and then decline and nadir near day 20 that lasts through day 30 [3, 8, 9].
Manifestations. Symptoms of moderate Hem-ARS is due to exposure to levels
of ionizing radiation around 3-4 Gray. Severe Hem-ARS is seen at ionizing radiation
doses from 4 Gy [2, 4]. While ARS can affect many organ systems (e.g., dermal,
cardiovascular), acute lethality generally results from destruction of the hematopoietic
system (“Hem-ARS”) or related complications (e.g. sepsis).
RADIATION INJURY
Ionizing radiation (IR) may consist of particulate or electromagnetic radiation.
Simulation of ARS for drug development and research purposes likely involves
electromagnetic radiation. IR comes from the portion of the electromagnetic spectrum
characterized by high frequency and short wavelength. Biological damage results from
the absorption and deposition of energy in cells and tissues. This energy deposition
occurs non-homogenously and therefore requires much less total energy to cause damage
than non-ionizing radiation [15]. Damage induced by ionizing radiation encompasses
two primary categories: initial damage and bystander damage. The importance of
understanding the effect a novel radiomitigant has on mitigating the bystander effect may
help to expand the treatment window that the compound may be first administered and
retain efficacy.
Initial Effect
The two causes of initial damage from directly irradiating cells are the charged
particles that directly interact with cellular structures (direct action), and free radical
generation which induces double strand breaks and oxidative stress (indirect action).
The energy deposited in a cell when it is irradiated is primarily absorbed by water leading
to the nearly instantaneous production of radical intermediates. These intermediates are
then free to react with other cellular structures.
5

Figure 1-4 Characteristic Lymphocyte Kinetics after Varying Radiation Doses.
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Bystander Effect
Signals are produced by the initially damaged cells and are transferred through
media and to a lesser extent through gap junctions. The damage caused to unirradiated
cells through these signals is a phenomenon known as bystander or non-targeted effects.
Generally, the term ‘Bystander Effect’ is used in the setting of non-therapeutic use of
radiation such as in an accident or nuclear attack because there is no intended ‘target’ for
the radiation.
Mechanisms of Radiation-Induced Cell Death
Apoptosis. The process of programmed cell death known as apoptosis plays a
crucial role in the biological effects caused by ARS. It is involved in both normal
cellular regulations in organs and in disease states. Organs which demonstrate high
proliferative and hematopoietic activity have a higher baseline level of apoptosis.
Apoptosis is characterized by specific cellular changes including chromatin condensation,
mitochondrial swelling, DNA cleavage, and loss of membrane integrity. Apoptosis may
proceed via a Caspase-8 or Caspase-9 dependent pathway; however they converge during
execution initiated by cleavage of Caspase-3 (Figure 1-5) [16].
Intrinsic. Apoptotic cell death which is initiated from within the cell results in
death via the intrinsic pathway, also known as mitochondrial or Caspase-9 dependent cell
death. It has recently been reported that death from Hem-ARS requires intrinsic
apoptosis [17].
Extrinsic. Apoptotic cell death which is initiated outside the cell results in death
via the extrinsic pathway, also known as Caspase-8 dependent cell death or death
receptor pathway. Extrinsic apoptosis occurs without mitochondrial involvement.
Mitotic Cell Death. The process known as mitotic cell death or mitotic
catastrophe results when a mitotic arrest occurs during which intrinsic apoptotic pathway
hallmarks become activated.
COMBINED INJURY
In the aftermath of a nuclear detonation it is feasible that there would be
combination injuries involving damage from both the radiation coupled with wounds of
varying severity. TBI in combination with vascular, dermal, or muscular injuries will
decrease survival. Due to the importance of considering realistic scenarios, a compound
being considered for an ARS indication must contemplate efficacy in a combined injury
setting.

7

Figure 1-5 Simplified Apoptotic Pathway.
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BIOMARKERS
The use of biomarkers in the setting of ARS has been primarily investigated for
use in dosimetry [18, 19]. Renewed interest in biomarkers for use as pharmacodynamic
or surrogate endpoint markers emerges in light of the quest for development of
pharmaceutical treatments for ARS.
Circulating Blood Counts
The most widely used biomarker is complete blood counts (CBC). CBC analysis
has been used both to indicate dosimetry and therapeutic response [13, 20-22].
Specifically, the kinetics of circulating blood cells (granulocytes, lymphocytes, and
platelets) are used to retrospectively estimate radiation dose, extent of hematopoietic
injury, and likelihood of spontaneous recovery without treatment [9, 23]. CBC analysis
is very useful, in indicating the extent of damage, however, due to reports that function
may be impaired despite increased circulating numbers, CBC counts may not be the best
way to evaluate recovery [7, 22].
Amylase
Serum amylase is used as an indicator of damage to the parotid gland by radiation
[24, 25]. Serum amylase is the result of interphase cell death of serous salivary cells. It
must be measured within 0.5-2 days of the initial radiation event in order to correlate
elevated levels with exposure [14, 24]. In non-human primates mates, significant intersubject variability was observed when measuring serum amylase, with somewhat less
variability in plasma amylase [14]. Serum amylase returns to baseline within a few days
after radiation exposure, thereby limiting the use of amylase to predict efficacy of
countermeasures.
Flt3-Ligand
The Flt3-ligand (FL) is a 34 kDa cytokine which works synergistically with other
hematopoietic growth factors (HGF) to induce the proliferation of pluripotent
hematopoietic progenitor and stem cells [19, 26]. The Flt3-ligand has been used in a
clinical setting as late as day 20 post TBI exposure as a measure of the extent of
hematopoietic exposure and correlates with hematopoietic nadir [27].
Citrulline
Citrulline is an amino acid produced by enterocytes and used as an indicator of
gastrointestinal damage [27]. It may be measured in plasma by chromatographic
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methods, and has been shown to reflect actual mucosal damage rather than absolute
radiation dose.
AVAILABLE INTERVENTIONS
Although there is a single product, amifostine, approved by the FDA for
administration prior to radiation, there are currently no known approved drugs that can be
administered after TBI exposure to enhance survival due to ARS.
Radioprotectants
Prophylactic potassium iodide administration to protect the thyroid from exposure
to excess 132I, Chelating agents such as diethylene triamine pentaacetic acid (“DTPA”) to
decrease exposure by binding and promoting urinary excretion and similarly, laxatives,
and absorbing agents such as Prussian blue to limit GI absorption or high oral doses of
calcium to compete with intestinal absorption of milk contaminated with strontium90.
Amifostine is a thiol compound under investigation as a radioprotectant. It has been used
to prevent mucositis caused by head-and-neck irradiation but must be administered in
advance of radiation exposure. Furthermore, its side effects (hypotension) would limit its
use in emergency first responders [28].
Biologicals
Growth factors are present abundantly in the circulation of people suffering from
radiation injury [9]. The use of biological products such as G-CSF for the treatment of
ARS is controversial. Agents that have not been approved by the FDA as radiomitigants
but are under investigation as regenerators include cytokines such as granulocyte colony
stimulating factor (“G-CSF”) and granulocyte-macrophage colony stimulating factor
(“GM-CSF”). Both must be given parenterally in a sophisticated medical setting as with
bone marrow transplant. Various lipopeptide agonists of Toll-like Receptors (e.g.,
TRL2/TRL6) are under investigation as an aid to bone marrow transplantation. Other
TRL agonists are under investigation for treatment of Hem-ARS and oral mucositis
following head and neck therapeutic irradiation.
Supportive Care
The use of supportive care is critical for optimum survival outcome in ARS,
particularly at low TBI doses. Supportive care includes administration of antibiotics,
fluids, blood products, isolation from secondary infections, and regulation of body
temperature.
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Bone Marrow Transplant
With regard to Hem-ARS, bone-marrow transplants (BMT) have been used for
irradiated victims without success [1-3]. 27 of the 31 patients that received BMT died.
The four survivors rejected the transplant and spontaneously repopulated with their own
stem cells [1, 4]. Furthermore, bone marrow transplants would not be practical after a
large scale disaster involving large numbers of patients requiring treatment.
CENTRAL HYPOTHESIS
The ideal treatment for ARS would be a physically stable compound that could be
easily and rapidly administered to large numbers of people exposed to a range of
radiation doses. The treatment should retain effectiveness when administered as a single
dose no sooner than 24 hours after exposure. The treatment should result primarily in
improvement in survival and secondarily in alleviation or improvement in associated
morbidities.
A drug approved for use in the treatment of ARS must attain approval through the
path set forth by the so-called “Animal Rule” because ethical considerations prevent preapproval efficacy testing in human subjects. The “Animal Rule” is encompasses four
primary pillars: (1) understanding the mechanism of the toxicity of the substance
(radiation) and its prevention or substantial reduction by the product (2) demonstrating
the effect in more than one animal species that is expected to react with a response that is
predictive for humans (3) demonstrating efficacy in the animal study endpoint that is
clearly related to the desired benefits in humans, and (4) characterizing the
pharmacokinetics and pharmacodynamics in such a way that allows selection of an
effective human dose.
Specific aim 1 (Chapter 2) focused on identifying primary endpoints in
established and novel in vivo radiation models. In this aim we tested our lead compound,
KZ-41, for efficacy on our primary endpoint- 30 day mortality. We also developed an in
vivo model to evaluate the effect of radiation on vascular injury, specifically clotting
abnormalities. We tested the efficacy of KZ-41 in restoring thrombus formation after
radiation in this novel model.
In specific aim 2 (Chapter 3), we wanted to focus on the pathways involved in
indirect damage caused by radiation. Our aim was to develop a model that would allow
testing of agents administered at least 24 hours after the initial radiation injury. To this
end, we developed an in vitro bystander effect model using human U937 cells, and tested
the effect KZ-41 had on pathways involved in apoptotic cell death. We also compared
the effect next-generation radiomitigating compounds to KZ-41 in the bystander effect
model.
Specific aim 3 (Chapter 4) focused on initial pharmaceutical profiling of nextgeneration radiomitigant KZ-157. We first developed a LC-MS/MS assay to measure
11

KZ-157 and its primary metabolites in biological matrices. We then measured protein
binding, susceptibility to P450 metabolism, and characterized the concentration-time
profile after i.v. and oral administration to rats.
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CHAPTER 2. IN VIVO RADIATION INJURY
INTRODUCTION
There is growing concern that the potential for nuclear attack is increasing. Small
scale attacks could involve hundreds to thousands of people exposed to total body
irradiation (TBI) [1]. Radiation exposures greater than 1 Gy, involving a significant
portion of the body and delivered at a relatively high dose rate induces Acute Radiation
Syndrome (ARS). Such radiation exposure can be from a nuclear accident (e.g.,
Chernobyl), from a military event (e.g., Hiroshima and Nagasaki), or through a terrorist
incident. Victims whose TBI dose ranges from 2-6 Gy, eliciting the response known as
the hematopoietic syndrome, will be most likely to be saved with treatment. It is
estimated that without supportive care (antibiotics and transfusions), a radiation dose of
approximately 3.5-4.5 Gy will result in death of 50% of persons exposed within 60 days
[3, 5, 6], and that nearly all untreated persons exposed to doses greater than 6 Gy will die
within 30 days of exposure [2]. The primary causes of death of persons suffering from
Hem-ARS are hemorrhage and infection due to the dose-dependent damage to the
hematopoietic stem cells.
There is an urgent unmet therapeutic need for radiomitigating (administered at
least 24 hours after radiation injury) and radioprotecting compounds (administered less
than 24 hours after radiation injury) which produce an improvement in survival.
Although the endpoint of improving survival seems to be clear-cut, in situations
such as nuclear accident or attack, there will likely be additional injuries secondary to the
radiation exposure. It has been estimated that as many as 60-70% of ARS patients will
have other injuries, and these patients will have a significantly lower LD 50/60 , as
secondary injury negatively impacted survival [5, 29]. Additional injuries increase the
probability of introduction of infection that a compromised hematopoietic system cannot
combat. Hematopoietic recovery must be attained or the patient will have no chance to
recover from other injuries [9]. Therefore, hematopoietic support is essential at all
radiation doses relevant to induce ARS.
Little is known about the effects of vascular injury in the setting of high doses of
total body irradiation simulating a nuclear accident or attack. Total body irradiation
delivered in large doses, to most or all of the body in a short period of time induces ARS
and causes widespread effects in the exposed organism. The hematopoietic syndrome
occurs even at the lowest doses that cause ARS, at approximately an LD 50/30 in mammals
[30]. The hematopoietic syndrome encompasses two sub-syndromes characterized by
leucopenia and thrombocytopenia. Our focus in the combined radiation model is to
evaluate the initial steps of wound healing in the vasculature primarily early thrombus
formation, translating to subjects presenting with the hematopoietic syndrome who die
from hemorrhage caused by thrombocytopenia [30].
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Radiation injury models are often established where they are routinely
implemented due to additional variables that must be characterized including type of
electromagnetic radiation (γ-ray vs. x-ray), source (60Co vs. 137Cs), dose rate, and normal
bacterial flora found in the local vivarium. It is nearly impossible in a non-GLP facility
to directly implement an established model without minor modifications. Therefore, it is
of critical importance to clearly outline and account for as many variables as possible
when designing a radiation model.
Unique challenges are presented when developing and characterizing a combined
injury model in addition to those discussed for radiation injury models. The desire to
produce the most robust model must be delicately weighed against approaching relevant
radiation doses and endpoints. Also, it is widely accepted that excessive handling and
manipulations cause a shift in both the radiation dose required to cause lethality and the
time to reach such an endpoint. This is of particular importance when dealing with
smaller model types, such as mice. Special consideration must be taken when choosing
the timing of both insults, radiation dose used, supportive care required, extent of
secondary insult, and timing (in relation to injuries) of the endpoint measurement. All of
these factors are intimately connected, and changes in one parameter must not be made
after the model is established without measuring the impact on all other relevant factors.
MATERIALS AND METHODS
Animals
Animals were purchased from Jackson Labs (Bar Harbor, ME). Animals were
maintained under specific pathogen-free conditions with controlled temperature (22° C)
and humidity (50%) and on 12-hr light/dark cycles. Animals were allowed a minimum
acclimation period of 72 hours from time of arrival prior to subjection to any procedure.
Standard laboratory food and tap water were available ad libitum.
Survival Study. Female C57/BL/6 mice at least 12 weeks old were used. These
studies were reviewed and approved by the Animal Care and Use Committee of the
Veterans Hospital, Memphis, TN.
Imaging Study. Male C57/BL/6 mice weighing 25-30g were used. These
studies were reviewed and approved by the Animal Care and Use Committee of the
University of Tennessee Health Science Center.
Irradiation and Treatment
A radioactive cesium 137 (137Cs) source was used for irradiation. KZ-41 was
prepared as a solution in 0.9% Sodium Chloride at a concentration of 10 mg per mL.
KZ-41 was synthesized as previously described in Dr. Duane Miller’s laboratory [5].
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Survival Study. Animals were irradiated at a dose rate of approximately 3
Gy/minute. A dose of 6.5 Gy was delivered uniformly to the entire body of each animal.
Animals were irradiated un-anesthetized in groups of 5 on a rotating platform
(Figure 2-1). Treatments were administered as a single dose 25 hours after TBI. The
“treatment” group received KZ-41 (100 mg/kg, s.q.), the “vehicle” group received 0.9%
Sodium Chloride (10 µL per 1 gram body weight, s.q.).
Imaging Study. Animals were irradiated at a dose rate of approximately 8
Gy/minute. A dose of 6 Gy was delivered uniformly to the entire body of each animal.
Animals were irradiated individually in the upright position on a rotating platform while
anesthetized (Figure 2-2). Animals were divided into 3 groups for treatment. Treatment
began 12 hours after TBI, and continued every 24 hours for the duration of the study.
The “treatment” group received KZ-41 (100 mg/kg, i.p.), the “vehicle” group received
0.9% Sodium Chloride (10 µL per 1 gram body weight), and the “sham” group received
no injection.
Murine Survival
After irradiation, and administration of treatement 26 hours after TBI, animals
were monitored closely. The number of animals surviving in each group was
documented for a period of 30 days.
Dorsal Window Surgery
Surgery was carried out as described previously [3, 4] with modifications. All
surgical procedures were carried out aseptically. After the animal was anesthetized, a
suitable area of skin on the dorsum was marked for hair removal with a clipper followed
by use of hair remover lotion. The surgical area was disinfected with alcohol and
betadine. A thin dorsal skin fold was lifted from the back and sandwiched between two
titanium plates (Figure 2-3). The titanium plates were firmly fixed with three screws and
nuts through the holes made in the fold. The skin was sutured to the top of the plates for
added stability. A circular section of the skin on one side of the skin fold along with its
cutaneous tissue and fascia was incised through the window of the dorsal skinfold
window chamber (DSFC) assembly to expose the blood vessels and the striated muscle of
the opposing skin of the dorsal skin fold. Antibiotic ointment containing bacitracin zinc,
polymyxin B sulfate and neomycin sulfate was applied to the edges of the incised wound
and a glass window fixed with a snap ring on top of the exposed area inside the DSFC
(Figure 2-4). Animals received analgesic every 12 hours for the first 48 hours after
surgery. Animals were allowed 3 days to recover after dorsal skin fold chamber fixation
prior to baseline measurements and radiation.
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Figure 2-1 Delivering TBI for Survival Study.
Unshielded mice were irradiated unanesthetized 5 at a time on a rotating platform. The
dose rate was approximately 3 Gy/min and a total dose of 6.5 Gy (LD80/30) was
delivered.
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Figure 2-2 Delivering TBI for Imaging Studies.
Window bearing anesthetized mice were irradiated individually on a rotating platform
without shielding. The dose rate was approximately 7 Gy/min and a total dose of 6 Gy
was delivered.

17

Figure 2-3 Dorsal Skinfold Window Apparatus.

Figure 2-4 Mouse Fixed with DSFC.
C57/BL6 mice were surgically fixed with the dorsal window and allowed to recover for 3
days prior to further manipulation.
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Intravital Microscopy
Window-bearing animals were anesthetized and received an intra-orbital injection
of rhodamine 6G (0.4 mg/kg body weight) for leukocyte visualization. All experiments
were carried out using an industrial grade microscope (Nikon MM-11) with two light
sources, bright-field (Opti-Quip 75 W xenon) and fluorescent (Nikon 150 W mercury).
Experiments were viewed on a video monitor and recorded for off-line processing. The
video images were analyzed off-line using MetaMorph software (Universal Imaging Co.).
Rolling and Adhered (stationary for > 30 seconds) leukocytes were quantified and
recorded.
Induction of Vascular Injury
The snap ring and glass window covering the dermal vasculature was removed.
The tissue was slightly swabbed with sterile cotton tipped applicator. Immediately prior
to injury induction animals were injected with Rhodamine 6G so that leukocytes and
platelets would be visible microscopically. The vascular injury was induced by “nicking”
a vessel with a sterile 30-gauage needle. Once the nick was induced, a new cover slip
was placed over the tissue and secured with a metal snap ring (Figure 2-5). Animals
were immediately placed on the imaging platform for intra-vital imaging. Animals were
injured (vascular injury) every 24 hours beginning 24 hours after TBI to establish model
parameters (Figure 2-6).
Blood Collection
Window-bearing animals were anesthetized with ketamine/xylazine (87:13, i.p.)
and blood was collected via cardiac puncture into plasma separator tubes containing
lithium heparin. Blood was gently mixed by inversion and immediately placed on ice
until analysis and processing. Processed plasma (centrifuged at 10,000 x g 10 min 4° C)
was aliquoted and stored at -80° C until cytokine/chemokine analysis.
CBC Analysis
Complete blood analysis was performed on heparinized whole blood with a
Beckman Coulter® Ac•T diff™ Analyzer as quickly as possible after collection (< 1
hour).
Cytokine/Chemokine Analysis
Following CBC analysis, blood was processed and stored as described above.
Cytokine concentrations in the plasma of animals from all groups was analyzed using the
Luminex platform.
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Figure 2-5 Low Magnification Image of Dermal Vasculature.
Low magnification view of the dermal vasculature following surgical implantation of
DSFC. Red arrow indicates an ideal site for injury induction.

Figure 2-6 Imaging Study Timeline.
Window implantation occurred on study day 1 with radiation on day 3. Daily treatments
began 12 hours after radiation and continued through the end of the study. Vascular
injury was induced on study day 6, with imaging immediately following. A second
image was collected 24 hours after injury (Study day 7) to evaluate flow restoration.
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Data Analysis
All data are expressed as mean plus or minus standard deviation. P values of <
0.05 were considered statistically significant.
RESULTS
Murine Survival
The primary endpoint of this study was 30-day mortality. Animals treated with a
single dose of KZ-41 26 hours after lethal total body irradiation showed an approximate
40% improvement in survival when compared with vehicle (saline) treated animals
(Figure 2-7).
Clot Formation
The primary endpoint in our imaging model was clot formation. Initial clot in
control (unirradiated animals) occurred within 2 minutes of injury (Figure 2-8A), and
evidence of remodeling could be observed as early as 8 minutes after vascular injury.
There was no difference in clot formation when vascular injury was induced 24 or 48
hours after TBI compared to control. There was no clot formation when vascular injury
was induced 72 hours after TBI (Figure 2-8B). 96 hours after TBI animals demonstrated
fragile vasculature and poor window quality which prevented consistent vascular injury
and analysis (Table 2-1). Induction of vascular injury 72 hours after TBI was optimal for
treatment evaluation in this model; therefore, all treatments were evaluated under this
time scheme. In untreated animals injured 72 hours after TBI, no clot formed in 5 of 6
animals measured (Table 2-1). Animals receiving KZ-41 treatment every 24 hours
beginning 12 hours after TBI, showed significant improvement in clot formation
compared with untreated animals (Figure 2-8C), with clots forming in 7 out of the 8
animals measured (Table 2-1).
Flow Restoration
The restoration of flow in the injured vessel both upstream and downstream of the
injury was analyzed 24 hours after vascular injury. TBI significantly decreased
restoration of flow when vascular injury was induced 72 hours after radiation (1/6 TBO
vs. 5/6 Control animals, Table 2-1). Three daily treatments with KZ-41 beginning 12
hours after TBI resulted in flow restoration in 43% of the treated animals (3/7) compared
with 17% of TBI alone animals, however, this improvement was not statistically
significant.
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Figure 2-7 Effect of KZ-41 on Murine 30 Day Survival.
KZ-41 (100 mg/kg or Vehicle (normal saline) was administered once 25 hours after lethal
total body irradiation (LD 80/30 ).
n = 24-26 per group
p < 0.05

22

Figure 2-8 Effect of KZ-41 on Radiation-Induced Clotting Abnormalities.
Clot formation after vascular injury in (A) Unirradiated Controls (B) Irradiated + Vehicle
(Normal Saline), and (C) Irradiated + KZ-41 (100 mg/kg).

Table 2-1 Effect of KZ-41 on Clot Formation.
Group
Unirradiated
Vehicle

Clot
Restoration
5/6 (83%)
1/6 (17%)*

Flow
Restoration
5/6 (83%)
1/6 (17%)*

KZ-41

7/8 (88%)#

3/7 (43%)

Mice were irradiated (6 Gy TBI) and treated (vehicle was normal saline, 100 mg/kg KZ41, s.q.) every 24 hours beginning 12 hours post TBI. Vascular injury was induced 3
days post TBI and cot formation was immediately assessed. Flow restoration was
measured 24 hours following vascular injury.
*Unirradiated control vs. irradiated vehicle treated mice (p < 0.05)
#KZ-41 vs. vehicle treated irradiated mice (p < 0.05)
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CBC Analysis
Circulating platelet and leukocyte counts were measured in animals receiving TBI
72 hours prior to vascular injury. Blood was collected and analyzed at the completion of
the study (96 hrs post TBI). There was a significant decrease in both platelet and
leukocyte numbers in the periphery (Figures 2-9, 2-10). Animals treated with KZ-41 did
not have elevated platelet or leukocyte counts compared with untreated animals (Figures
2-9, 2-10).
Cytokine Analysis
Circulating KC and TNF-α concentrations were measured in animals receiving
TBI 72 hours prior to vascular injury. Blood was collected and analyzed at the
completion of the study (96 hrs post TBI). There was a significant increase in circulating
KC and TNF-α in animals receiving TBI alone compared to control animals. There was
no difference in measured cytokine levels between KZ-41 and untreated animals
(Figures 2-11, 2-12).
DISCUSSION
There is currently no small-molecule approved for administration after exposure
to radiation doses causing acute radiation syndrome to improve survival. The primary
causes of death in individuals suffering from the heme-syndrome of ARS are infection
and hemorrhage. These individuals exhibit decreased levels of circulating leukocytes and
platelets (pancytopenia). The complications present in patients affected by ARS at the
lower heme doses are also present and problematic in higher ARS doses (GI and CNS);
therefore, it is important to have in vivo models in place to evaluate and develop potential
treatments for all doses of ARS.
We have demonstrated that KZ-41 significantly improves survival when
administered as late as 26 hours after lethal total body radiation. KZ-41 is a novel small
molecule with an attractive biopharmaceutical profile which makes it an ideal drug
candidate. Although the survival study met the efficacy endpoint for ARS, we wanted to
further investigate the mechanisms by which KZ-41 was exerting its effect, particularly
in the setting of combined vascular injury, while simultaneously addressing an unmet
need for combined injury models.
The described combined injury model was optimized using 6 Gy Total Body
Irradiation coupled with vascular injury on day 3 post TBI (Figure 2-6). Complete blood
analysis, cytokine measurements, and other parameters may also be studied in the same
animals as the imaging when coupled with careful interpretation. Imaging endpoints in
our study were clot formation and restoration of flow, however, leukocyte activity and
vessel diameter at the site of injury and in adjacent (irradiated only) vessels as well as
vessel permeability in uninjured vessels may also be studied. Under the conditions
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Figure 2-9 Leukocyte Counts 4 Days post TBI.
Blood was collected from window bearing mice on study day 7 and analyzed for
circulating leukocytes.
*Unirradiated control vs. irradiated vehicle treated mice (p < 0.05)
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Figure 2-10 Platelet Counts 4 Days post TBI.
Blood was collected from window bearing mice on study day 7 and was analyzed for
circulating platelet counts.
*Unirradiated control vs. irradiated vehicle treated mice (p < 0.05)

26

KC Concentration (x 10^3 pg/mL)

90

*

80
70
60
50
40
30
20
10
0
Control

IR

KZ-41

Figure 2-11 KC Concentration 4 Days post TBI.
Blood was collected from window bearing mice on study day 7 and was analyzed for
circulating KC concentration.
*Unirradiated control vs. irradiated vehicle treated (IR) mice (p < 0.05)
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Figure 2-12 TNF-α Concentration 4 Days post TBI.
Blood was collected from window bearing mice on study day 7 and was analyzed for
circulating TNF-α concentration.
*Unirradiated control vs. irradiated vehicle treated (IR) mice (p < 0.05)
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described, there was a significant reduction in the formation of a clot immediately
following vascular injury and restoration of vascular flow in the injured vessel compared
with unirradiated control animals. The novel radiomitigant KZ-41 significantly restored
clot formation, and improved the incidence of flow restoration although not to
significance when first administered 12 hours following lethal TBI. The effect of KZ-41
on clot formation in this model was not related to circulating platelet numbers as
evidenced to similar platelet counts as untreated irradiated animals. We hypothesize that
the effect demonstrated in the imaging model on clot formation is due to platelet
function, and further analysis is planned to test these hypothesis.
Although this model has proved invaluable in our drug evaluation studies, there
are limitations that should be considered. The surgery and subsequent radiation the
animals receive places them in an extremely fragile state, and in our opinion prevents
escalation of the dose beyond 6 Gy outside of acute endpoints. Also due to the physical
burden of the window, one must evaluate cytokine and chemokine parameters carefully.
The model that we have developed and described is a unique, versatile model to study
combined radiation and vascular injury. This is the first radiation combined injury model
described which allows investigation of vascular response in the setting of ARS [6]. This
model may be expanded or condensed based on the specific aims of the project.
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CHAPTER 3. IN VITRO MECHANISM
INTRODUCTION
Damage induced by ionizing radiation encompasses two primary categories:
initial damage and bystander damage (or non-targeted effects). The two causes of initial
damage from directly irradiating cells is the charged particles that directly interact with
cellular structures (direct action), and free radical generation which induces double strand
breaks and oxidative stress (indirect action). Signals are produced by the damaged cells
and are transferred through media and to a lesser extent through gap junctions [31]. The
damage caused to unirradiated cells through these signals is a phenomenon known as the
bystander effect.
In the setting of ARS understanding the bystander effect is of particular interest
when discussing the efficacy elicited by a radiomitigant. By definition, a radiomitigant is
administered after the radiation event. Therefore, for a clear understanding of the
mechanism of action of a radiomitigating compound one must investigate the downstream events that occur after the initial “trigger” radiation event. A recently published
study investigated the transcriptomes of both directly irradiated and bystander (via media
transfer) cells and concluded that they are very similar, suggesting a propagation of injury
phenomenon [32].
Various groups have investigated the bystander effect via directly irradiating a
single cell(s) by using micro beam radiation and observing the effects on the surrounding
cells [33]. This experimental setup has primarily focused on the role gap junctions play
in the bystander effect phenomenon. Investigations into bystander signaling using mixed
populations (directly irradiated and unirradiated) of cells as well as multiple cell types
have been also been conducted. The important role of death receptor signaling in the
bystander effect has also been demonstrated using medium transfer experiments [32, 34,
35].
Although radiation-induced bystander effects have been demonstrated for a
variety of biological endpoints, we focus on effector caspase activation as an indicator of
apoptosis and bystander effect. Extracellular-initiated apoptosis signaling executes down
one of two primary pathways. Mitochondrial independent apoptosis is mediated by
death-receptor ligand, activation of Caspase-8 then Caspase-3, and ending in apoptosis.
Mitochondrial dependent apoptosis is mediated by Bax, Bak, Bcl-2, Cytrchrome C
release, activation of Caspase-9 then Caspase-3, and ending in apoptosis. The final step
(Caspase-3 activation) prior to apoptosis is common to both pathways, and is thus an
attractive surrogate marker for measuring apoptosis.
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MATERIALS AND METHODS
Cell Line
Human monocytic lymphoma cells (U937) stably transfected with a gentamycin
resistant gene were purchased from ATCC. Cells were grown in RPMI 1640 media
supplemented with 10% and 50 µg/mL concentration of gentamycin in a 37° C incubator
with 5% CO 2 .
Irradiation
Cells received a dose of 7 Gy from a 137Cs source at a dose rate of approximately
8 Gy/minute on a rotating plate to ensure uniform exposure.
Treatment
U937 cells were divided into two different treatment groups as discussed below.
Treatments were dissolved into low serum (1%) medium at a concentration of 100 mM
and serially diluted to the desired concentration. All wells were treated in triplicate.
Directly Irradiated Cells
Cells were plated in MultiScreen HTS -PCF filter plates (Millipore, Billerica, MA)
approximately 18 hours prior to irradiation in growth medium containing 1% FBS and 50
µg/mL at a concentration of 1 x 106 cells per mL. Cells were incubated under serum
starved conditions at 37º C with 5% CO 2 . All treatments (including vehicle) were
conducted immediately (approximately 0.5 hours) prior to irradiation. Treatments were
dissolved in fresh medium containing 1% FBS and 50 µg/mL gentamycin. Cells were
incubated at 37º C with 5% CO 2 for various lengths of time following radiation at which
time cells were analyzed for markers of damage, repair, and apoptosis.
Bystander Effect Cells
Actively growing (bystander) cells were plated in MultiScreen HTS -PCF filter
plates (Millipore, Billerica, MA) in growth medium at a concentration of 1 x 106 cells per
mL. Growth medium was removed via vacuum filtration. Treatments were dissolved in
conditioned medium obtained after a 24 hour incubation post irradiation from directly
irradiated cells. Conditioned medium +/- treatments were then placed on the actively
growing unirradiated cells and gently mixed for 1 minute on an orbital plate shaker.
Cells were incubated at 37º C with 5% CO 2 for an additional 24 hours (referred to as 2424) at which time cells were analyzed for markers of damage, repair, and apoptosis.
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Apoptosis
Markers of apoptosis and DNA damage in the samples were measured in cell
lysate per manufacturer’s protocol using the Beadlyte® 3-Plex Apoptosis Signaling Kit
and the pH2A.X Beadmate® (Millipore, St. Charles, MO) paired with the Luminex®
200™ System (Luminex Corporation, Austin, TX). Controls and samples (50 µL) were
mixed with 25 µL of bead solution (fluorescent beads conjugated to antibodies for Active
Caspase-3, GAPDH, Cleaved PARP, and pH2A.X) and incubated overnight at 4° C.
Wells were washed and beads resuspended in assay buffer. Biotin-conjugated antibodies
(anti-Active Caspase-3, GAPDH, Cleaved PARP, and pH2A.X) were added and
incubated for 1.5 hours. Streptavidin-Phycoerythrin was added and incubated 30
minutes. Unbound reagents were removed and fluorescence intensity reported as the
median of 100 beads per analyte in each well. Median Fluorescent Intensity (MFI)
values are reported as the % change from baseline.
DNA Damage
Millipore pH2A.X Beadmate® multiplexed with the Millipore Beadlyte® 3-Plex
Apoptosis Signaling Kit (above) coupled with the Luminex platform.
Cell Death
Flow Cytometry was coupled with LIVE/DEAD® Cell Vitality Assay Kit with
C12-Resazurin and SYTOX® green stain to evaluate metabolically active (live),
metabolically inactive, and dead cells per manufacturer’s protocol (Molecular Probes).
Cells in suspension were incubated with 500 nM C12-Resazurin and 10 nM SYTOX
Green dye at 37° C for 15 minutes in the presence of 5% CO2. Cell-dye mixtures were
diluted and kept on ice until analysis by flow cytometry with fluorescence emission at
539 nm and 575 nm. C12-Resazurin is reduced to red-fluorescent C12-Resorufin in cells
that are metabolically active (delineated as live cells from this point forward). Dead cells
with compromised plasma membranes will uptake the green-fluorescent nucleic acid
stain SYTOX® Green dye, emitting green fluorescence. Metabolically inactive cells
emit reduced red-fluorescence due to their reduced metabolic rate, but will exclude the
green dye because they have intact membranes.
Death Receptor Ligand Quantification
Media samples were collected and stored at -80° C until analysis with Beadlyte®
multiplex cytokine analysis kit (Millipore, St. Charles, MO) paired with the Luminex®
200™ System. Standards and samples (50 µL) were mixed with 25 µL of bead solution
and incubated overnight at 4° C. Wells were washed and beads resuspended in assay
buffer. Multi-cytokine biotinylated antibodies were added and incubated for 1.5 hours.
Streptavidin-Phycoerythrin was added and incubated 30 minutes. Unbound reagents
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were removed and fluorescence intensity reported as the median of 75 beads per cytokine
in each well. Concentrations were interpolated by fitting fluorescence intensity from
unknowns to the standard curves.
ROS Evaluation
The ROS assay was carried out as previously described with minor
modifications[36]. Dicholorofluorescindiacetate (DCFH-DA) dye was used for this
assay. U937 cells were plated at a density of 150,000 cells/well in MultiScreen HTS -PCF
filter plates (Millipore, Billerica, MA). Plates were then irradiated with a dose of 7 Gy.
After 24 hours, media was removed via vacuum filtration. Cells were then re-suspended
in 100uL of 10uM DCFH-DA dye that had been reconstituted in DMSO and diluted in
PBS. The plate was then covered in aluminum foil and incubated for 5 minutes at 37° C.
Dye was then removed via vacuum filtration. Cells were reconstituted in 200uL phenol
red free RPMI. The plate was covered in foil and incubated for 30 minutes on a plate
shaker at room temperature. Cells were then transferred to a black 96-well plate, and the
plate was again covered in foil. The plate was incubated 30 minutes further at 37° C. A
Beckman Coulter DTX 880 Multimode Detector was used to read plate fluorescence with
excitation and emission settings at 485 and 535 nm respectively.
RESULTS
Direct Effect
Apoptosis after Direct Irradiation Exposure. The effect of a single dose of
ionizing radiation was evaluated on the U937 cell population over time. Activated
Caspase-3 was measured at 1, 4, 24, 36, and 48 hours after IR (ionizing radiation). A
bimodal increase was measured 24 and 48 hours after IR (Figure 3-1). No increase in
phosphorylated histone 2A (pH2A.X) was observed in the time points that were
measured (1, 4, 24, 36, and 48 hours) (Figure 3-2). Significant apoptotic cell death was
verified 24 hours post IR (Figure 3-3). The effect of KZ-41 (0.1, 1, 10, and 100 µM)
treatment 30 minutes prior to IR was investigated at both 24 hours and 48 hours after IR.
There was no significant effect on active Caspase-3 levels at either 24 or 48 hours after
IR (Figures 3-4, 3-5). There was no reduction in apoptotic cell death by KZ-41 24 hours
after IR, which correlates with the Caspase-3 measurements (Figure 3-6).
Death Receptor Ligand after Direct Irradiation Exposure. Tumor necrosis factor
alpha (TNF-α) was measured in the medium as a function of time (1, 4, 24, 36, and 48
hours) following radiation exposure. TNF-α levels are below detection at 1 hour after IR
exposure, however, may be detected as early as 4 hours post exposure. The maximum
TNF-α concentration detected in our experiment was observed at 24 hours after exposure
and was sustained at this elevated level through the last measured time point of 48 hours
after exposure (Figure 3-7). KZ-41, when administered 30 minutes prior to irradiation,
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Figure 3-1 Caspase-3 Activation after 7 Gy IR.
U937 cell were irradiated (7 Gy) and Caspase-3 activation was measured using Luminex
as a function of time as an indicator of apoptotic cell death.
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Figure 3-2 pH2A.X following 7 Gy IR.
U937 cell were irradiated (7 Gy) and DNA double strand breaks were measured as a
function of time using Luminex.
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Figure 3-3 Apoptotic Cell Death 24 Hours following 7 Gy IR.
U937 cell were irradiated (7 Gy) and stained with propidium iodide 24 hours later.
Apoptotic cell death was measured by flow cytometry.
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Figure 3-4 Effect of KZ-41 at 24 Hours on Radiation-Induced Direct Damage.
U937 cells were treated with KZ-41 (0-100 µM) and were immediately irradiated (7 Gy).
24 hours after radiation, Caspase-3 was measured by Luminex.
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Figure 3-5 Effect of KZ-41 at 48 Hours on Radiation-Induced Caspase-3 Activation.
U937 cells were treated with KZ-41 (0-100 µM) and were immediately irradiated (7 Gy).
24 hours after radiation, Caspase-3 was measured by Luminex.
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Figure 3-6 Effect of KZ-41 on Apoptotic Cell Death 24 Hours post Radiation
Injury.
U937 cells were treated with KZ-41 (0-100 µM) and were immediately irradiated (7 Gy).
24 hours after radiation, cells were stained with propidium iodide and apoptotic cell death
was measured by flow cytometry.
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dose-dependently (0.1-100 µM) reduced TNF-α concentration in the medium 48 hours
after irradiation (Figure 3-8).
Reactive Oxygen Species. Reactive Oxygen Species (ROS) significantly
increases 24 hours after irradiation, and KZ-41 (1 µM) significantly reduces ROS
(Figure 3-9).
Bystander Effect
Effect of Irradiation. The apoptotic effect 24 hours after a single transfer of
conditioned medium (transferred 24 hours after IR), hereby referred to as 24-24, was
measured via Caspase-3/7 activity to establish the possibility of a bystander effect in this
model system. There is significant accumulation of Caspase-3 24 hours after IR (Figure
3-10), and degradation of Caspase-3/7 occurs when stored at 37° C compared with -80º C
for 24 hours (Figure 3-11). There are differences in total and soluble Caspase-3/7 at 2424 (Figures 3-11, 3-12), but not in cellular levels (Figure 3-13).
Effect of KZ-41 and Next Generation Compounds. KZ-41 caused a dosedependent (0.1-100 µM) reduction in Caspase-3/7 in the 24-24 CM experimental setup
(Figure 3-14). Next generation compounds (Figure 3-15) were analyzed at 1 µM and
compared to the efficacy of KZ-41 (Figure 3-16). KZ-157 demonstrated a significant
improvement over KZ-41 in reducing Caspase-3/7 levels under this model system at a 1
µM concentration.
DISCUSSION
A single cell type in vitro model where both direct damage and the bystander effect may
be monitored and used for drug efficacy testing in the setting of radiation injury has been
presented. In the U937 cell line, we have shown that a radiation dose of 7 Gy is
sufficient to induce apoptotic cell death under our experimental conditions. At 24 hours
after IR, we were able to measure a significant increase in both Caspase-3 and apoptotic
cell death (Figures 3-1, 3-3), which is different from a previously published study who
did not observe significant cell death prior to 30 hours after 7 Gy RI [36]. This group did
not show the apoptosis data prior to 48 hours but they did mention their findings. One
marked difference between the Kim group’s findings and ours is serum starvation. The
Kim group did not serum starve prior to radiation, and all of our data is reflective of
serum starvation (1% FBS) prior to radiation. This difference is an important one to note
because serum starvation arrests cells in the G0/G1 phase in the cell cycle [15].
Approximately 40% of actively growing U937 cells are in S phase which is the most
radiation resistant phase of the cell cycle [37, 38]. Furthermore, although highly effective
at promoting survival, we have demonstrated that our lead compound, KZ-41, has no
effect on Caspase-3 or apoptosis when administered prior to radiation injury (Figures 34, 3-5, 3-6). Due to the nature of the therapeutic deficiency that we are -α after IR as a
first step in developing a bystander effect model. We demonstrated a
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Figure 3-7 TNF-α Concentration following 7 Gy Radiation Exposure.
U937 cells were irradiated (7 Gy). TNF-α concentration in the medium was measured by
Luminex as a function of time after irradiation.
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Figure 3-8 Effect of KZ-41 on TNF-α Production 48 Hours post Radiation.
U937 cells were treated with KZ-41 (0-100 µM) and were immediately irradiated (7 Gy).
48 hours after radiation, TNF-α concentration in the medium was measured by Luminex.
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Figure 3-9 Effect of KZ-41 on ROS 24 Hours post Radiation.
U937 cells were treated with KZ-41 (1 µM) immediately prior to irradiation (7 Gy). 24
hours after radiation, ROS was measured.
*p < 0.05 when compared with non-IR cells
#p < 0.05 when compared with IR cells
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Figure 3-10 Caspase-3/7 Activity 24 Hours post CM Transfer.
U937 cells were irradiated (7 Gy) and allowed to incubate for 24 hours. Medium was
removed from irradiated cells and placed on unirradiated bystander cells. 24 hours after
medium transfer, Caspase-3/7 was measured with luminescent plate reader.
*p < 0.05
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Figure 3-11 Stability of Caspase-3/7 in Cell Culture Medium.
U937 cells were irradiated (7 Gy) and allowed to incubate for 24 hours. Medium was
removed from irradiated cells and either frozen (-80º C) or stored at culture conditions
(37º C) for 24 hours. Caspase-3/7 was measured with luminescent plate reader.
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Figure 3-12 Soluble Caspase-3/7 24 Hours post CM Transfer.
U937 cells were irradiated (7 Gy) and allowed to incubate for 24 hours. Medium was
removed from irradiated cells and transferred to unirradiated bystander cells. Cells and
conditioned medium were allowed to incubate for an additional 24 hours. Caspase-3/7
(luminescence) was measured by plate reader in cell-free medium.
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Figure 3-13 Cellular Caspase-3/7 from Bystander Cells 24 Hours post CM
Transfer.
U937 cells were irradiated (7 Gy) and allowed to incubate for 24 hours. Medium was
removed from irradiated cells and transferred to unirradiated bystander cells with KZ-41
(0-100 µM). Cells and conditioned medium was allowed to incubate for an additional 24
hours. Caspase-3/7 (luminescence) was measured by plate reader in washed cells.
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Figure 3-14 Effect of KZ-41 on the Radiation-Induced Bystander Effect.
U937 cells were irradiated (7 Gy) and allowed to incubate for 24 hours. Medium was
removed from irradiated cells and transferred to unirradiated bystander cells with KZ-41
(0-100 µM). Cells and conditioned medium was allowed to incubate for an additional 24
hours. Caspase-3/7 (luminescence) was measured by plate reader.
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Figure 3-15 Chemical Structure of KZ-157.
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Figure 3-16 Next-Generation Analog Screening.
U937 cells were irradiated (7 Gy) and allowed to incubate for 24 hours. Medium was
removed from irradiated cells and transferred to unirradiated bystander cells with
treatments (KZ-41 and KZ-157 at 1 µM). Cells and conditioned medium was allowed to
incubate for an additional 24 hours. Compounds were screened for their potential to
reduce Caspase-3/7 compared to KZ-41.
*p ≤ 0.05, # p < 0.01 when compared to KZ-41
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time-dependent effect in TNF-α concentration, with a peak beginning at 24 hours after IR
(Figure 3-7). We also established that although KZ-41 has no effect on Caspase-3
activation when administered prior to IR, there is a dose-dependent reduction in TNF-α
48 hours after IR (Figure 3-8). KZ-41 was also effective in reducing reactive oxygen
species levels, another player in the propagation of radiation-induced injury, and possibly
applicable in the bystander effect [36]. We demonstrated that a bystander effect can be
elicited in the U937 cell line through soluble factors by a series of conditioned medium
transfer experiments (Figure 3-10). We hypothesize that a variety of soluble factors such
as TNF-α, TRAIL, and Fas ligand are the initiators of this bystander effect, and once the
bystander cells are exposed to these soluble factors, they initiate the death cascade. We
believe that the death cascade progresses through both mitochondrial dependent and
independent pathways.
Caspase-3/7 is not stable at 37º C, which is the ambient temperature used during
the experiments, therefore, only a fraction of the Caspase 3/7 measured at the 24-24 time
point is residual from the conditioned medium transfer (Figure 3-11). Also, conditioned
medium from irradiated cells may be collected and stored at -80º C for use in these
experiments with success; however, there is some loss of potency in inducing Caspase3/7 in untreated cells (data not shown). KZ-41 dose-dependently reduced Caspase-3/7
levels 24 hours after transfer of conditioned medium taken from cells 24 hours after
irradiation (Figure 3-14).
Although we continue to evaluate the efficacy and mechanism of KZ-41 as a
radiomitigant, we recognize the importance in discovering a potent next-generation
compound for use in Acute Radiation Syndrome. We, therefore, conducted a screen of
next generation KZ-41 analogs in the U937 bystander effect model. The caffeic acid
ester of KZ-41 (KZ-157) was shown to be significantly more potent at reducing Caspase3/7 in this bystander effect model, compared to KZ-41 alone (Figure 3-16). Due to
published reports on the value of antioxidants for use in radioprotection coupled with our
screening data, we will move forward with pre-clinical pharmaceutical characterization
of chlorogenic acid analogs, specifically KZ-157 (Figure 3-15). We hypothesize that
KZ-157 will have more potent life-saving effect in the in vivo survival studies due to the
effect of the antioxidant (caffeic acid) portion of the molecule in addition to the proven
benefit of KZ-41.
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CHAPTER 4. PHARMACOKINETIC MODELING OF NEXT GENERATION
QUINIC ACID ANALOGS
INTRODUCTION
The interest in developing natural products for various indications has rapidly
grown in recent years. Inflammation plays a vital role in many disease states, and is
therefore a fundamental focus for developing natural products. Central in natural antiinflammatory agents are antioxidants. Radiation injury is one such disease state where
antioxidants have shown a proven benefit. The only Food and Drug Administration
approved drug for the indication of radioprotection is Amifostine and some of its efficacy
may be attributed to free radical scavenging properties [12]. Amifostine, however, does
not retain the attractive low toxicity profile of many natural products.
Many antioxidants are naturally occurring in food. One such antioxidant is
chlorogenic acid. There are large quantities of chlorogenic acid in coffee, blueberries,
chocolate, beer, tea, and many other commonly consumed foods and beverages [39-42].
Chlorogenic acid is the ester of quinic acid and caffeic acid (CA), and may be broken
back into its component parts by esterases found in the blood or by enzymatic
degradation by gut bacteria [40, 43]. Once separated, quinic acid has very low
bioavailability due to rapid degradation by gut bacteria. As a result of the low
bioavailability, the biological activity of chlorogenic acid is attributed to the antioxidant
potential of caffeic acid.
Our goal was to retain the active portion of chlorogenic acid (caffeic acid) and to
substitute a known biologically active molecule for the quinic acid portion. We
substituted KZ-41 for the QA portion of the molecule because of its proven efficacy in
our desired setting, Acute Radiation Syndrome. The result was KZ-157 (Figure 4-1), a
next generation KZ-41 molecule and chlorogenic acid derivative.
Theoretically, KZ-157 is a pro-drug, however, it is unique in that we hypothesize
that its primary metabolites (caffeic acid and KZ-41) would also be active. In order to
achieve initial pharmaceutical profiling of KZ-157, an analytical method was required so
that KZ-157 and its metabolites could be measured in a biological matrix.
MATERIALS AND METHODS
Animals
Double or single cannulated male Sprague-Dawley rats weighing 200-300g
obtained from Harlan Laboratories (Indianapolis, IN) were used for this study. The
locations for the cannula were the jugular vein and/or the femoral vein. Animals bearing
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single cannula were used for oral dosing studies, and animals bearing double cannula
were used for intra venous (I.V.) studies. All animal experiments were submitted,

Figure 4-1 Chemical Structure of Chlorogenic Acid Derivative KZ-157.
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reviewed, and approved (Protocol # 1629) by the University of Tennessee Animal Care
and Use Committee.
Treatments
A weight based dosing strategy was used in these studies. A dose of 1 mg/kg KZ157 (Figure 4-1) was administered to each animal based on the weight of the subject the
morning of dosing via the intravenous or oral rout. The dosing solution was 10 mg/mL,
therefore a total volume ranging from 0.20 - 0.26 mL was delivered to each animal.
PK Sampling Strategy
The blood sampling strategy was the same for both oral and I.V. studies, and was
as follows: 0, 5, 15, 30, 45, 60, 120, 240, 480, 720, and 1440 minutes after drug
administration. Blood was collected from the jugular vein cannula (JVC), and placed in
a BD Plasma Separator Microtainer® (BD Biosciences, San Jose, CA) containing lithium
heparin, gently mixed, and placed on ice until processing JVC was flushed and the
collected blood volume was replaced with 0.9% Sodium Chloride (NS) following each
blood collection.
Pharmacokinetic Data Analysis
Plasma concentration-time data were analyzed using non-compartmental analysis
in WinNonlin 5.0.1 (Pharsight Corporation, Mountain View, CA). The maximum plasma
concentration (C max ) observed after oral dosing and the time at which it was observed
(T max ) were determined by direct inspection of the individual plasma concentration-time
profiles. The terminal half-life (t 1/2 ) was calculated as 0.693 divided by the terminal
phase rate constant ( λ z ).
T 1/2

=

0.693
λz

The area under the plasma concentration-time curve from time 0 to infinity
(AUC 0-∞ ) was calculated by the trapezoidal rule with extrapolation to time infinity. The
total plasma clearance (CL) was calculated as the dose (D (ng)) divided by the observed
AUC 0-∞ .
CL =

D
AUC 0-∞
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The fraction of drug absorbed (F) was calculated by dividing the oral AUC 0-∞ by
the intravenous AUC 0-∞ . The oral clearance (CL oral ) was obtained by dividing the CL by
F.
F

=

AUC 0-∞, I.V.

CLoral = CL
F

AUC 0-∞, oral

Volume of distribution (V) was calculated as the dose divided by the product of
AUC 0-∞ λ z. The volume of distribution following the oral dose (V ora l) was determined
by dividing the volume by F.
V =

V oral

D

=

V
F

AUC 0-∞ * λz

LC-MS/MS Method
Chromatographic separation was carried out using Shimadzu (Columbia, MD)
LC-10ADvp pumps with a Leap (Carrboro, NC) CTC PAL autosampler HPLC system.
The analytes were separated with a methanol-2mmol/L ammonium acetate solution
(65/35, v/v) mobile phase and an Agilent Zorbax C18 column (5µm particle size, 4.6 mm
x 150 mm). A flow rate of 0.5 mL/min and an injection volume of 10 µL were used. The
total LC run time was 8 minutes. The column and autosampler were maintained at
ambient temperature for the duration of the method. Detection of the analytes and
internal standard was performed on an API 4000 Q TRAP mass spectrometer equipped
with an electrospray ion source (Applied Biosystems Sciex, Foster City, CA) operated in
negative-ion mode. The LC and MS parameters were controlled by Analyst software
version 5.0. Multiple reaction monitoring (MRM) scan type was used to monitor the
transition from precursor to product ion for KZ-157 m/z 394 → 161, CA m/z 179 → 135,
KZ-41 m/z 232 → 85, and IS m/z 352 → 191. The dwell time for all analytes was 250
msec.
Standard Samples
Stock solutions of CA, KZ-41, and KZ-157 were prepared in methanol at a
concentration of 1.0 mg/mL. The stock solutions were combined and further diluted in
methanol to make working solutions for standards (20000, 10000, 5000, 2500, 1000, 500,
and 100 ng/mL). The IS stock solution was further diluted in methanol to make an IS
working solution (1500 ng/mL). Analyte working solutions were then spiked (10X) into
rat plasma to make calibration standards. The resulting concentrations of standards and
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QC samples were 2000, 1000, 500, 250, 100, 50, 25, and 12.5 ng/mL. Calibration
standards were prepared fresh daily.
Sample Extraction from Plasma
Sample extraction was optimized based on a method previously published [44].
Plasma aliquots were processed 8 at a time to ensure minimum time between thaw and
processing. Aliquots of 100 µL plasma were thawed on ice, and immediately mixed with
10 µL IS, and 1 mol/L hydrochloric acid and vortexed for one minute. Ethyl-ether-ethyl
acetate (1:1, v/v) was added to the sample and vortexed for 10 minutes. The sample was
then centrifuged at 10,000 x g for 10 minutes at 4º C. The supernatant was transferred to
a clean tube and evaporated to dryness at 35º C under a stream of nitrogen (5 psi). The
residue was dissolved in 25 µL methanol, vortexed for 1 minute and centrifuged for 1
minute at 10,000 x g. The supernatant was transferred into an autosampler vial where 10
µL was injected into the LC-MS/MS system for analysis.
Rat Microsomal Stability
The role of Phase I metabolism was investigated using pooled rat liver
microsomes (Cellzdirect, Austin, TX) by monitoring disappearance of parent compound.
25 µL Compound (50 µM in 0.1 phosphate buffer) was combined with 25µL (10 mg/mL)
microsomal protein solution and NADPH regenerating solution (1.3 mM NADP+, 3.3
mM glucose-6-phosphate, 3.3 mM MgCl 2 , and 1 unit/mL glucose-6-phosphate
dehydrogenase in pH 7.4 phosphate buffer solution). Reactions were incubated at 37° C
for 0, 15, 30, 45, 60, and 90 minutes. Duplication of this experiment was performed
simultaneously with the following modifications: (1) heat inactivated (denatured)
microsomal protein was used as a negative control and (2) a second known substrate
(propanalol) was used as a positive control for microsomal activity. At the end of
incubation, 10 µL internal standard (KZ-124 1 µg/mL in Methanol) and 10 µL
Hydrochloric Acid (1M) was added and mixed. 0.8 mL ethyl-ether-ethyl acetate was
added and the mixture was vortexed on high for 3 minutes. Samples were centrifuged at
10,000 rpm at 4° C for 10 minutes. The supernatant was divided and stored at -80° C.
Prior to analysis, samples were thawed and evaporated to dryness under a stream of
nitrogen gas. The pellet was resuspended in 25 µL methanol and analyzed by LCMS/MS.
In Vitro Protein Binding
Protein binding was analyzed using equilibrium dialysis. RED® (rapid
equilibrium dialysis) inserts (Pierce Biotechnology Inc, Rockford, IL) coupled with a
base plate was used for this analysis. Concentrations ranging from 0.01 to 10 µg/mL
were tested in rat plasma. Plasma was mixed (200µL) with the test compound was
placed in one side of the chamber and 350µL blank isotonic phosphate buffer, pH 7.4 was
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placed in the other side of the chamber. The chambers were covered and incubated with
100 rpm orbital shaking at 37° C for 4-6 hours to allow equilibrium to be achieved.
Volume of each chamber was checked at the end of the incubation to ensure no volume
shift occurred. 50µL aliquots of plasma and buffer were separately analyzed to
determine the drug concentration using LC-MS/MS. The percent free compound was
calculated as the ratio of the compound concentration in the buffer and plasma.
RESULTS
LC-MS/MS Method
Each analyte monitored had a distinct retention time under the established
conditions. The retention times for Caffeic Acid, KZ-41, KZ-157 and the internal
standard were 2.38, 3.27, 3.9, and 4.44 minutes respectively (Figures 4-2, 4-3, 4-4, 4-5).
The retention times were consistent when measured simultaneously (Figure 4-6).
Pharmacokinetics of KZ-157
KZ-157 demonstrates two-compartment pharmacokinetics (Figure 4-7). Plasma
concentrations were below the limit of quantification by 2 hours after both intravenous
and oral administration (Figures 4-7, 4-8). KZ-157 appeared rapidly in the plasma after
oral administration with the Cmax being less than 15 minutes in all animals. The
pharmacokinetic parameters of each animal dosed via the oral and intravenous routes are
described in Tables 4-1 and 4-2, respectively. The volume of distribution was 7066 and
1909 mL for oral and I.V. respectively. The half life was very short at 53 minutes for
oral and 34 minutes for I.V. There was a large amount of variability, particularly with
the oral dosing regimen. The fraction of drug absorbed following oral dosing is low at
approximately 28% (Table 4-3).
Protein Binding of KZ-157
The extent of protein binding of KZ-157 to proteins in rat plasma using
equilibrium dialysis was determined to be 43.8% bound.
Microsomal Stability
KZ-157 is very resistant to metabolism by liver microsomes. Greater than 70% of
KZ-157 remains after a 90 minute incubation with liver microsomes.
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Figure 4-2 Retention Time of Caffeic Acid.
The retention time of caffeic acid, a primary metabolite of KZ-157, was determined
under the specified LC-MS/MS conditions as 2.3 minutes.
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Figure 4-3 Retention Time of KZ-41.
The retention time of KZ-41, a primary metabolite of KZ-157, was determined under the
specified LC-MS/MS conditions as 3.27 minutes.
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Figure 4-4 Retention Time of KZ-157.
The retention time of KZ-157 was determined under the specified LC-MS/MS conditions
as 3.9 minutes.
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Figure 4-5 Retention Time of IS.
The retention time of the internal standard used in quantification of KZ-157 was
determined under the specified LC-MS/MS conditions as 4.44 minutes.
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Figure 4-6 Simultaneous Detection of KZ-157 and Primary Metabolites.
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Figure 4-7 Concentration-Time Profile of KZ-157 after Intravenous
Administration.
KZ-157 (1mg/kg) was administered intravenously to Sprague-dawley rats (n=4). Serial
plasma samples were collected and quantified using LC-MS/MS.
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Figure 4-8 Concentration-Time Profile of KZ-157 after Oral Administration.
KZ-157 (1mg/kg) was administered orally to Sprague-dawley rats (n=4). Serial plasma
samples were collected and quantified using LC-MS/MS.
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Table 4-1 Pharmacokinetic Data for KZ-157 after Oral Administration.
F

Subject

CLoral
Vss oral
(mL/min) (mL)

AUC
T 1/2
(min*ng/mL) (min)

5
6
7
8

80
159
81
286

7570
13636
6773
286

1248
6306
12327
3491

65.37736
59.74138
57.75
27.94355

Mean
Standard Deviation

152
97

7066
5461

5843
4792

53
17

0.28

Table 4-2 Pharmacokintic Data for KZ-157 after Intravenous Administration.
Subject

CL
(mL/min)

Vss
(mL)

AUC
(min*ng/mL)

T 1/2
(min)

1
2
3
4

49
50
55
42

1733
2910
1763
1231

20339
20127
18209
23639

25.29197
64.76636
23.97924
22.42718

Mean
Standard Deviation

49
5

1909
710

20579
2254

34
20

Table 4-3 Mean Pharmacokinetic Parameters of KZ-157 after Oral and IV
Administration.
Route
IV
Oral

T 1/2
min
34
53

CL
mL/min
49
152
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V ss
mL
1909
7066

F

0.28

DISCUSSION
KZ-157 is a chlorogenic acid derivative and a next-generation analog of KZ-41.
It was shown to potentially be more potent than its precursor KZ-41 in the in vitro
bystander effect screen (Figure 3-17). Our aim was to establish initial pharmaceutical
profiling of KZ-157. In order to measure this novel chlorogenic acid derivative, we
developed an LC-MS/MS method coupled with an extraction method to quantify KZ-157
and its metabolites in a small biological sample.
Other investigators have reported rapid initial absorption and bimodal peaks
following a two-compartment model after oral administration of chlorogenic acid [45,
46]. These groups administered high doses (greater than 200 mg/kg) and were able to
monitor the primary chlorogenic acid metabolites quinic acid and caffeic acid. Our initial
aim was to quantify the KZ-157 metabolites CA and KZ-41 and we acknowledge the
importance of monitoring them. The dose we administered to the animals was
comparatively much lower (1 mg/kg) than those investigators who conducted metabolite
monitoring, and we feel that with a modest increase in the administered dose we will
have quantifiable levels of the most common metabolites. There are also conflicting
reports of stability in plasma with some suggesting that it is susceptible to esterase
activity in rat plasma while stable in human plasma. Our data suggests that KZ-157 is
susceptible to plasma or whole blood esterase activity in that we can detect CA and KZ41 analyte peaks as early as 5 minutes after intravenous administration of KZ-157 (data
not shown). Modeling these metabolites is critical due to our hypothesis that the parent
compound, KZ-157, along with each of the individual metabolites, CA and KZ-41, will
have biological activity. It has been reported that chlorogenic acid is poorly absorbed
from the intestine, and that bioavailability is largely dependent on individual gut
microflora [40, 47]. Our data suggests that KZ-157 is rapidly absorbed in its native form
as indicated by its detection 5 minutes following oral administration.
KZ-157 demonstrates two-compartment pharmacokinetics, and rapid absorption
following oral administration. The relative resistance to metabolism by liver microsomes
coupled with the rapid elimination observed suggests high susceptibility to other
mechanisms of degradation such as esterase activity. The high variability observed
during the early time points following oral administration and relatively low
bioavailability (as demonstrated by a low fraction absorbed following oral
administration) could be partly due to the mechanism by which this compound is
absorbed.
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CHAPTER 5. SUMMARY
There are currently no FDA approved radiomitigators for the treatment of Acute
Radiation Syndrome. An urgent need exists for safe and effective drugs that can be
administered at least 24 hours after high dose total body irradiation to large numbers of
patients. Effects to the hematopoietic system play a central role in the pathogenesis and
primary causes of morbidity and mortality in patients presenting with ARS. The
hallmark of HEM-ARS is hematopoietic dysfunction. The hematopoietic failure rapidly
translates to pancytopenia resulting in a decreased ability to fight infection and increased
bleeding potential. Death from HEM-ARS is primarily related to sepsis and hemorrhage.
Hematopoietic effects are present in all patients, regardless of the total absorbed dose, in
patients affected by ARS due to the presence of overlapping syndromes. In light of these
considerations, there is much effort being invested into developing radiomitigating
compounds specifically for HEM-ARS.
In our quest to develop a radiomitigating compound for use in HEM-ARS we first
had to identify a lead compound and demonstrate efficacy in our primary endpoint
(Specific Aim 1). Quinic acid derivative KZ-41 was identified as our compound of
interest and we tested its efficacy in a murine lethal total body irradiation 30 day
mortality study. KZ-41 significantly improved survival when administered 25 hours after
lethal (LD 80/30 ) total body irradiation. Armed with this information, we sought to learn
more about the efficacy of KZ-41, particularly in the setting of preventing radiationinduced abnormalities in thrombus formation.
There are few established animal models to study the effects of ARS eliciting
doses of radiation and potential mitigation by a compound of interest. Therefore, we
developed a live animal imaging model to study the effects of vascular injury in the
setting of high dose TBI (HEM-ARS doses). We identified our primary endpoint as
thrombus formation, and optimized the time after irradiation to maximize the difference
in thrombus formation. We correlated thrombus formation with circulating platelet
numbers as a secondary endpoint. We then tested the radiomitigating (12 hours after
TBI) efficacy of KZ-41 on radiation-induced abnormalities in thrombus formation. KZ41 significantly increased the probability of thrombus formation after irradiation without
affecting the circulating platelet numbers. With this second piece of efficacy data, we
focused our aim on the mechanism of action of KZ-41.
To investigate the mechanism of action of the radiomitigating effects of KZ-41
(Specific Aim 2) we chose to develop an in vitro model in human U937 cells. We chose
this monocyte-like cell line because of published reports concluding that death from
HEM-ARS requires mitochondrial dependent apoptosis in hematopoietic cells. Because
we were developing radiomitigating compounds, we believed that we required a model
that allowed us to investigate indirect or bystander effects. We demonstrated that a
bystander effect can be elicited in the U937 cell line through soluble factors by a series of
conditioned medium transfer experiments, and that KZ-41 dose-dependently reduces
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Caspse-3/7 activation which is partly due to inhibition of Caspase-8. Although we are
making progress towards the mechanism of action of KZ-41, further studies are required.
In an effort to improve upon our existing lead compound, KZ-41, we were
interested in incorporating the proven efficacy of antioxidants in radiation injury
(Specific Aim 3). Our goal was to retain the active portion of chlorogenic acid (caffeic
acid) and to substitute a known biologically active molecule for the quinic acid portion.
We substituted KZ-41 for the QA portion of the molecule because of its proven efficacy
in our desired setting, Acute Radiation Syndrome. The result was KZ-157 a next
generation KZ-41 molecule and chlorogenic acid derivative. We investigated the initial
pharmacokinetic parameters of KZ-157 both in vivo and in vitro. We first developed an
LC-MS/MS method that enabled us to quantify KZ-157 and its primary metabolites in
biological matrices. We then administered KZ-157 to rats both intravenously and orally
to characterize the pharmacokinetics, and evaluated plasma protein binding and stability
in the presence of liver microsomes. KZ-157 demonstrates two-compartment
pharmacokinetics with a rapid absorption and a low bioavailability following oral
administration and is rapidly eliminated.
In summary, we have identified and demonstrated radiomitigating efficacy of
novel radiomitigant KZ-41 in multiple animal models. We are beginning to understand
the mechanism of action of its radiomitigating effects via the in vitro assay that we
developed. The in vitro model that we have developed may also be used to screen for
next-generation radiomitigating compounds.
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